Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1530

1.

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J.

Br J Cancer. 2014 Mar 18;110(6):1497-505. doi: 10.1038/bjc.2014.80. Epub 2014 Feb 25.

PMID:
24569463
2.

Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.

Wu YM, Chen ZJ, Liu H, Wei WD, Lu LL, Yang XL, Liang WT, Liu T, Liu HL, Du J, Wang HS.

Oncotarget. 2015 Sep 22;6(28):25588-601. doi: 10.18632/oncotarget.4436.

PMID:
26160845
3.

Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.

Lin D, Kuang G, Wan J, Zhang X, Li H, Gong X, Li H.

Oncol Rep. 2017 Feb;37(2):895-902. doi: 10.3892/or.2016.5311. Epub 2016 Dec 12.

PMID:
27959422
4.

Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.

Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM.

Breast Cancer Res Treat. 2014 Jun;145(3):593-604. doi: 10.1007/s10549-014-2979-6. Epub 2014 May 9.

PMID:
24810497
5.

SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.

Jin MS, Hyun CL, Park IA, Kim JY, Chung YR, Im SA, Lee KH, Moon HG, Ryu HS.

Tumour Biol. 2016 Apr;37(4):4743-53. doi: 10.1007/s13277-015-4231-3. Epub 2015 Oct 30.

PMID:
26515337
6.

Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.

Shrivastava S, Jeengar MK, Thummuri D, Koval A, Katanaev VL, Marepally S, Naidu VGM.

Biofactors. 2017 Mar;43(2):152-169. doi: 10.1002/biof.1315. Epub 2016 Sep 1.

PMID:
27580587
7.

Epithelial-to-mesenchymal transition markers to predict response of Berberine in suppressing lung cancer invasion and metastasis.

Qi HW, Xin LY, Xu X, Ji XX, Fan LH.

J Transl Med. 2014 Jan 24;12:22. doi: 10.1186/1479-5876-12-22.

PMID:
24456611
8.

Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.

Bräutigam K, Mitzlaff K, Uebel L, Köster F, Polack S, Pervan M, Steinert G, Rody A, Liedtke C.

Anticancer Res. 2016 Jun;36(6):2759-66.

PMID:
27272786
9.

Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.

Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Hatano T, Tanaka S, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M.

Anticancer Res. 2018 Jan;38(1):401-410.

PMID:
29277801
10.

Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.

Kawano S, Asano M, Adachi Y, Matsui J.

Anticancer Res. 2016 Apr;36(4):1553-61.

PMID:
27069131
11.

Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.

Kim S, Lee J, Jeon M, Nam SJ, Lee JE.

Cytokine. 2015 Sep;75(1):151-8. doi: 10.1016/j.cyto.2015.05.020. Epub 2015 Jun 15.

PMID:
26088755
12.

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.

Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC.

Breast Cancer Res. 2015 Feb 22;17:25. doi: 10.1186/s13058-015-0527-x.

PMID:
25849745
13.

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.

Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K.

Springerplus. 2014 Aug 8;3:417. doi: 10.1186/2193-1801-3-417. eCollection 2014.

PMID:
25140293
14.

miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer.

Yu J, Xie F, Bao X, Chen W, Xu Q.

Mol Cancer. 2014 May 24;13:121. doi: 10.1186/1476-4598-13-121.

PMID:
24885626
15.

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT.

Mol Cancer Ther. 2015 Dec;14(12):2773-81. doi: 10.1158/1535-7163.MCT-15-0243. Epub 2015 Sep 17.

PMID:
26384399
16.

Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.

Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu J, Jin W.

Oncotarget. 2015 Jun 30;6(18):16352-65.

PMID:
25970785
17.

Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.

Kitahara H, Hirai M, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S.

Oncol Rep. 2016 Dec;36(6):3139-3144. doi: 10.3892/or.2016.5189. Epub 2016 Oct 21.

PMID:
27779690
18.

Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.

Hsu HY, Lin TY, Hwang PA, Tseng LM, Chen RH, Tsao SM, Hsu J.

Carcinogenesis. 2013 Apr;34(4):874-84. doi: 10.1093/carcin/bgs396. Epub 2012 Dec 28.

PMID:
23275155
19.

Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.

Dezső Z, Oestreicher J, Weaver A, Santiago S, Agoulnik S, Chow J, Oda Y, Funahashi Y.

PLoS One. 2014 Aug 29;9(8):e106131. doi: 10.1371/journal.pone.0106131. eCollection 2014.

PMID:
25171249
20.

Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling.

Khan S, Shukla S, Sinha S, Lakra AD, Bora HK, Meeran SM.

Int J Biochem Cell Biol. 2015 Jan;58:1-16. doi: 10.1016/j.biocel.2014.10.028. Epub 2014 Nov 7.

PMID:
25448414

Supplemental Content

Support Center